Immix Biopharma, Inc
Immix Biopharma, Inc., based in Los Angeles, CA, is a pioneering company focused on the development of innovative cell therapies for AL amyloidosis and other serious diseases. Their lead product, NXC-201, utilizes advanced sterically-optimized CAR-T technology, aiming to redefine treatment protocols and enhance patient outcomes within the realm of oncology.
With a commitment to addressing critical challenges in the treatment of serious diseases, Immix Biopharma is actively conducting clinical trials and expanding its therapeutic platform. The company is positioned as a key player in the healthcare sector, offering significant potential for both patient impact and investor interest.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.